FDA Flags Lower Efficacy For Merck&39;s Keytruda Roche&39;s Tecentriq In Frontline Bladder Cancer Trials

In patients with previously untreated metastatic bladder cancer with low PDL1 expression PD1 drugs alone don&39;t work as well as...&160;&160;&160;&1…
Read the full story: Bioportfolio Latest News